Expression and clinical value of MAGE-A3 in cervical cancer tissues and PBMC
HU Meil1, WANG Yahui1, HE Haipeng2, YAN Feng1, YANG Jinlan1, LIU Jiaqi3, WANG Zhifang1, ZHAO Qian1, ZHANG Shan3, ZHANG Xiaoxiao1
1. Department of Obstetrics and Gynecology, Baoding Maternal and Child Health Hospital, Baoding 071000, China; 2. Department of Obstetrics and Gynecology, Affiliated Hospital of Hebei University, Baoding 071000, China; 3. Department of Obstetrics and Gynecology, Baoding Maternal and Child Health Hospital, Baoding 071000, China
Abstract：Objective To investigate the expression and clinical value of melanoma-associated antigen-A3 (MAGE-A3) in cervical cancer tissues and peripheral blood mononuclear cells (PBMC). Methods A total of 96 patients with cervical conectomy or extensive hysterectomy due to cervical lesions from Baoding Maternal and Child Health Hospital and the Affiliated Hospital of Hebei University from May 2020 to May 2022 were selected by convenient sampling, and divided into cervical cancer group (56 cases) and cervical squamous intraepithelial lesion (SIL) group (40 cases) according to postoperative pathological results. Immunohistochemical method was used to detect the expression of MAGE-A3 protein in the pathological tissues. Real-time fluorescent quantitative PCR method was used to detect the expression level of MAGE-A3mRNA in cervical lesion tissues and PBMC, and to analyze the correlation between the expression of MAGE-A3 mRNA in cancer tissues and PBMC of cervical cancer patients and serum tumor markers, as well as the relationship between the expression of MAGE-A3 protein in cancer tissues and clinicopathological characteristics. To explore the diagnostic value of MAGE-A3 mRNA expression in cancer tissue and PBMC for cervical cancer. Results The positive rate of MAGE-A3 protein expression in cervical cancer tissue was correlated with FIGO stage, tumor diameter, differentiation degree, lymph node metastasis and infection with high-risk HPV (P<0.05), but not with age or pathological type (P>0.05). The mRNA expression levels of MAGE-A3 in cancer tissue and PBMC in cervical cancer group were (1.33±0.46) and (1.70±0.49), respectively, which were significantly higher than those in SIL group (0.59±0.20) and PBMC group (0.92±0.33) (P<0.05). Serum levels of SCC-Ag[(3.87±1.69) ng/ml] and CA-125[(48.62±15.10) U/ml] were significantly higher than those of SIL group [(0.70±0.32) ng/ml, (25.36±8.33) U/ml] (P<0.05). The expression positive rate of MAGE-A3 protein in cervical cancer group (66.07%) was significantly higher than that in SIL group (30.00%) (P<0.05). The mRNA expression levels of MAGE-A3 in cancer tissue and PBMC of patients with cervical cancer were positively correlated with serum SCC-Ag and CA-125 (P<0.05). Conclusions The expression of MAGE-A3 in cancer tissue and PBMC of patients with cervical cancer is up-regulated, and it is related to the level of serum tumor markers and disease progression of patients. MAGE-A3 is expected to be an important marker for the diagnosis of early cervical cancer.
胡美丽, 王雅慧, 何海鹏, 严凤, 杨金兰, 刘佳麒, 王志芳, 赵倩, 张珊, 张笑笑. 宫颈癌癌组织及外周血单个核细胞中MAGE-A3的表达及其临床意义[J]. 武警医学, 2024, 35(6): 520-524.
HU Meil, WANG Yahui, HE Haipeng, YAN Feng, YANG Jinlan, LIU Jiaqi, WANG Zhifang, ZHAO Qian, ZHANG Shan, ZHANG Xiaoxiao. Expression and clinical value of MAGE-A3 in cervical cancer tissues and PBMC. Med. J. Chin. Peop. Armed Poli. Forc., 2024, 35(6): 520-524.
Crosbie E J, Einstein M H, Franceschi S, et al. Human papillomavirus and cervical cancer[J].Lancet, 2013, 382(9895): 889-899.
[2]
Bucchi L, Baldacchini F, Mancini S, et al. Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy[J]. Int J Cancer, 2019,144(5): 1017-1026.
Vander Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma [J]. Science, 1991, 254(5038): 1643-1647.
Imura M, Yamashita S, Cai L Y, et al. Methylation and expression analysis of 15 genes and three normally-methylated genes in 13 Ovarian cancer cell lines[J].Cancer Lett, 2006, 241(2):213-220.
Daudi S, Eng K H, Mhawech-Fauceglia P, et al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer [J]. PLoS One, 2014, 9(8): e104099.
[13]
Derré L, Cesson V, Lucca I, et al. Intravesical bacillus calmette guerin combined with a cancer vaccine increases local T-Cell responses in non-muscle-invasive bladder cancer patients[J].Clin Cancer Res, 2017, 23(3): 717-725.
2024, Vol. 35 
